Results 121 to 130 of about 183,958 (171)

A Perplexing Plexopathy After Pembrolizumab Therapy in Early-Stage Triple-Negative Breast Cancer. [PDF]

Curr Oncol
Baiyewun T, McNamara B, Aherne E, Bryan AJ, Twomey J, NiLoingsigh S, Ofi B, Power D, O'Reilly S.   +8 more
europepmc   +1 more source

Analysis of Plasma Epstein-Barr Virus DNA and Clinical Outcomes to Pembrolizumab or Chemotherapy in Recurrent/Metastatic Nasopharyngeal Cancer in KEYNOTE-122. [PDF]

Cancer Med
Chan ATC, Lee VHF, Hong RL, Ahn MJ, Chong WQ, Spreafico A, Kim SB, Ho GF, Caguioa PB, Ngamphaiboon N, Swaby RF, Wei B, Webber AL, Kang J, Gumuscu B, Yuan J, Siu LL.   +16 more
europepmc   +1 more source

Immunotherapy in triple-negative breast cancer: mechanisms of resistance and emerging approaches: a narrative review. [PDF]

J Yeungnam Med Sci
Koh SA.
europepmc   +1 more source

A Case Report of Promising Response to Combination Therapy With an Immune Checkpoint Inhibitor (Pembrolizumab) and Multi-Targeted Tyrosine Kinase Inhibitor (Pazopanib) in Metastatic De-Differentiated Chondrosarcoma. [PDF]

Cancer Rep (Hoboken)
Youssef M, Grimison P.
europepmc   +1 more source

Subcutaneous pembrolizumab: a meaningful advance in cancer treatment delivery. [PDF]

J Thorac Dis
Shimizu T.
europepmc   +1 more source

Clinical Outcomes of Pembrolizumab in Head and Neck Squamous Cell Carcinoma Subsites Excluded from the KEYNOTE-048 Trial. [PDF]

Curr Oncol
Yamashita G, Okada T, Okamoto I, Kondo T, Ito T, Fujii S, Kishida T, Aihara Y, Hanyu K, Ueda Y, Tokashiki K, Sato H, Harada Y, Momiyama K, Matsuki T, Kushihashi Y, Masubuchi T, Tada Y, Yamashita T, Tsukahara K.   +19 more
europepmc   +1 more source

Pembrolizumab-Associated Aortitis in a Patient With Triple-Negative Breast Cancer: A Case Report. [PDF]

Cureus
Ardila N, Guerrero Bermúdez CA, Tasco Múnera SA, Choi Park J.   +3 more
europepmc   +1 more source

Correction to: Astellas article: UK multidisciplinary recommendations on use of combination first-line enfortumab vedotin▼ and pembrolizumab in advanced urothelial carcinoma. [PDF]

Oncologist
europepmc   +1 more source

Case Report: Rapid recurrence of psoriasiform dermatitis upon sequential anti-PD-1 therapy with pembrolizumab and tislelizumab with 3-year follow-up. [PDF]

Front Immunol
Chi CC, Li ZY, Cai SQ, Tang ZL.
europepmc   +1 more source